Jump to navigation ☰ Menu Biostage Submits Investigational New Drug (IND) Application for Lead Product Candidate Cellspan™ Esophageal Implant for Treatment of Esophageal Conditions Biostage's technology has the potential to not only avoid multiple complex surgeries, but also improve the patient's quality of life compared to the current standard of care. >>> BIOSTAGE REPORTS Q3 2021 FINANCIAL RESULTS BIOSTAGE ANNOUNCES IND APPROVAL FROM FDA FOR ITS LEAD PRODUCT CANDIDATE CELLSPAN™ ESOPHAGEAL IMPLANT Next Esophageal Atresia: A Life-Threatening Condition that Demands Effective Treatment Approximately 1 in 4,000 babies, in the US alone, are born with this congenital defect. Find out how Biostage is working to answer this unmet medical need. >>> Cellspan™ Implants: Signal and Guide Regeneration Bioengineered implants guide the regeneration of a biological structure. Learn how stem cells adhere to and interact with the implant. >>> Privacy Policy Terms of Use Search Contact ©2021 Biostage. All rights reserved.